Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven Grinspoon, Pamela S. Douglas, Markella V. Zanni et al.|The Lancet HIV|2025Cited by 32
Effects of Integrase Inhibitor–Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIVMabel Toribio, Markella V. Zanni, Tricia H. Burdo et al.|Open Forum Infectious Diseases|2020Cited by 11
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Smith, Steven Grinspoon, Carlos Malvestutto et al.|Open Forum Infectious Diseases|2025Cited by 9
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J. Corley, Steven Grinspoon, Varun B. Dwaraka et al.|Clinical Infectious Diseases|2025Cited by 8
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T. Lu, Steven Grinspoon, Heather J. Ribaudo et al.|JACC Advances|2025Cited by 8